We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

69 hedge funds and large institutions have $40.2M invested in Relmada Therapeutics in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 26 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

222% more call options, than puts

Call options by funds: $1.67M | Put options by funds: $520K

1% less capital invested

Capital invested by funds: $40.7M → $40.2M (-$436K)

3.91% less ownership

Funds ownership: 44.93% → 41.02% (-3.9%)

13% less funds holding

Funds holding: 79 → 69 (-10)

58% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 26

60% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 15

Holders
69
Holders Change
-10
Holders Change %
-12.66%
% of All Funds
0.99%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
11
Reduced
26
Closed
15
Calls
$1.67M
Puts
$520K
Net Calls
+$1.15M
Net Calls Change
+$785K

Top Buyers

1
Millennium Management
Millennium Management
New York
+$1.61M
2
Franklin Resources
Franklin Resources
California
+$938K
3
SC
Shay Capital
New York
+$569K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$255K
5
ECM
ExodusPoint Capital Management
New York
+$220K

Top Sellers

1
VPC
Vestal Point Capital
New York
-$2.3M
2
DTC
Deep Track Capital
Connecticut
-$1.81M
3
TCM
Tang Capital Management
California
-$606K
4
OM
Opaleye Management
Massachusetts
-$389K
5
Marshall Wace
Marshall Wace
United Kingdom
-$343K
Name Holding Trade Value Shares
Change 		Change in
Stake
Franklin Resources
1
Franklin Resources
California
$4.36M +$938K +289,490 +29%
Vanguard Group
2
Vanguard Group
Pennsylvania
$4.07M – – –
Acadian Asset Management
3
Acadian Asset Management
Massachusetts
$3.84M -$22.3K -6,881 -0.6%
PCM
4
Parsons Capital Management
Rhode Island
$3.25M +$86.6K +26,750 +3%
PAI
5
Palo Alto Investors
California
$2.37M – – –
DTC
6
Deep Track Capital
Connecticut
$2.19M -$1.81M -559,940 -45%
BlackRock
7
BlackRock
New York
$1.84M -$17.6K -5,434 -0.9%
Millennium Management
8
Millennium Management
New York
$1.82M +$1.61M +497,469 +773%
VPC
9
Vestal Point Capital
New York
$1.59M -$2.3M -710,000 -59%
OM
10
Opaleye Management
Massachusetts
$1.56M -$389K -120,000 -20%
JP Morgan Chase
11
JP Morgan Chase
New York
$1.02M -$122K -37,557 -11%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$987K +$143K +44,004 +17%
Two Sigma Advisers
13
Two Sigma Advisers
New York
$786K -$162K -50,000 -17%
Deutsche Bank
14
Deutsche Bank
Germany
$729K – – –
Bank of America
15
Bank of America
North Carolina
$670K -$4.25K -1,311 -0.6%
Two Sigma Investments
16
Two Sigma Investments
New York
$620K -$38.7K -11,946 -6%
BCM
17
Bridgeway Capital Management
Texas
$587K – – –
SC
18
Shay Capital
New York
$569K +$569K +175,547 New
RC
19
RBF Capital
California
$536K – – –
Jacobs Levy Equity Management
20
Jacobs Levy Equity Management
New Jersey
$511K +$255K +78,779 +100%
Barclays
21
Barclays
United Kingdom
$473K – – –
UBS Group
22
UBS Group
Switzerland
$409K -$7.82K -2,415 -2%
Fidelity Investments
23
Fidelity Investments
Massachusetts
$378K +$84.8K +26,185 +29%
GCP
24
GSA Capital Partners
United Kingdom
$351K +$962 +297 +0.3%
MOS
25
MGO One Seven
Ohio
$324K – – –
1
2 3 4

RLMD Hedge Fund Activity: Q3 2024 in Review

69 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q3 2024, worth a combined $40.2M — down 1.1% from $40.7M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of RLMD and 6 opened new positions — a net loss of 9 holders — while 26 trimmed existing stakes and 11 added.

The largest buyer was Millennium Management, adding an estimated $1.61M. The largest seller was Vestal Point Capital, cutting an estimated $2.3M.

  • 69 institutional investors held Relmada Therapeutics (RLMD) as of Q3 2024, down from 79 in Q2 2024.
  • Funds reported $40.2M of Relmada Therapeutics stock for Q3 2024, down 1.1% quarter-over-quarter.
  • 6 funds opened new Relmada Therapeutics positions in Q3 2024 and 15 closed out, a net change of -9 holders.
  • The largest Relmada Therapeutics buyer in Q3 2024 was Millennium Management, an estimated $1.61M added.
  • The largest Relmada Therapeutics seller in Q3 2024 was Vestal Point Capital, an estimated $2.3M sold.

Based on aggregated 13F filings for Q3 2024.